Cardiac Surgery-Associated Acute Kidney Injury: Protecting the Kidneys When Fixing the Heart
Introduction
Cardiac surgery saves hundreds of thousands of lives every year — correcting coronary artery disease through bypass grafting, replacing diseased valves, repairing congenital defects, and treating aortic aneurysms. Yet the very interventions that save hearts can simultaneously damage kidneys. Cardiac surgery-associated acute kidney injury (CSA-AKI) is one of the most common and consequential complications of major cardiac procedures, affecting between 5% and 43% of patients depending on the definition used and the patient population studied.
AKI is a common and serious complication of cardiac surgery that has a significant impact on patient outcomes. There are various preoperative, intraoperative, and postoperative risk factors for the development of CSA-AKI which should be recognized and addressed as early as possible to expedite its diagnosis, reduce its occurrence, and prevent or ameliorate its devastating complications.
The research of Mohammad Najafi and colleagues at Tehran Heart Center — including his foundational Urology Journal publication and subsequent landmark paper on serum creatinine as an outcome predictor — has contributed directly to understanding how preoperative renal function predicts who will develop CSA-AKI and who will not. This knowledge shapes preoperative risk stratification, intraoperative management, and postoperative monitoring protocols at cardiac surgery centers worldwide.
Understanding CSA-AKI: Definition and Scope
How AKI Is Defined After Cardiac Surgery
In 2004, the Acute Dialysis Quality Initiative (ADQI) proposed a classification for acute renal failure based on the patient serum creatinine, urine output, glomerular filtration rate and clinical outcome: the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) classification. In 2007, the Acute Kidney Injury Network (AKIN) proposed a revised version of AKI classification to improve the sensitivity of AKI criteria.
The current standard is the KDIGO (Kidney Disease: Improving Global Outcomes) 2012 classification:
| Stage | Serum Creatinine Criterion | Urine Output Criterion | Clinical Implication |
| Stage 1 | Rise ≥ 0.3 mg/dL within 48h OR 1.5–1.9× baseline within 7 days | < 0.5 mL/kg/h for 6–12 hours | Mild; close monitoring |
| Stage 2 | 2.0–2.9× baseline within 7 days | < 0.5 mL/kg/h for ≥ 12 hours | Moderate; nephrology consultation |
| Stage 3 | ≥ 3× baseline OR ≥ 4.0 mg/dL OR initiation of RRT | < 0.3 mL/kg/h for ≥ 24h OR anuria ≥ 12h | Severe; high mortality risk |
The major challenge in applying these criteria to cardiac surgery is that current diagnostic methods for CSA-AKI have limitations, hindering early intervention and individualized patient management. Serum creatinine — the cornerstone of AKI diagnosis — is a lagging marker: it does not rise until 50–60% of nephron function is already lost, meaning clinically significant renal injury may be present for 12–24 hours before creatinine confirms it.
The Scale of the Problem
Cardiac surgery is a significant risk factor for AKI, affecting 5–43% of patients and leading to increased mortality, extended hospital stays, and substantial healthcare costs. Even patients with full kidney function recovery experience a heightened risk of CKD and mortality in the following years.
The consequences of CSA-AKI escalate dramatically with severity:
- Stage 1 CSA-AKI: approximately 2-fold increase in short-term mortality
- Stage 2 CSA-AKI: approximately 4-fold increase in short-term mortality
- Stage 3 CSA-AKI requiring renal replacement therapy: short-term mortality of 40–70%
Even “minor” post-cardiac surgery AKI — a creatinine rise that fully resolves before hospital discharge — is associated with an increased lifetime risk of CKD, ESRD, and cardiovascular death, making prevention of any degree of CSA-AKI a clinically meaningful goal.
Pathophysiology: Why Cardiac Surgery Injures the Kidney
The Cardiopulmonary Bypass Machine: Necessary but Harmful
Most cardiac operations require cardiopulmonary bypass (CPB) — a heart-lung machine that temporarily takes over cardiac and pulmonary function while the surgeon operates on a still, bloodless heart. CPB is essential for most complex cardiac operations, but it simultaneously exposes the kidney to multiple injury mechanisms:
Ischemia-reperfusion injury: The pathogenesis of CSA-AKI is multifaceted, involving reduced renal blood flow, dislodged emboli obstructing renal arteries, and detrimental effects from cardiopulmonary bypass including ischemia, hemolysis, inflammation, and oxidative stress. During CPB, non-pulsatile flow — the pump provides continuous rather than pulsatile pressure — reduces medullary perfusion more than cortical perfusion, predisposing the metabolically active tubular cells of the outer medulla to ischemic injury.
Hemolysis and free hemoglobin toxicity: Injured erythrocytes release cell-free hemoglobin and other heme-derived products. If these scavenging systems are overwhelmed during prolonged or excessive hemolysis, plasma levels of cell-free hemoglobin and heme increase, and their clearance relies on renal filtration. Renal cell exposure to cell-free hemoglobin results in increased oxidative stress, inflammation, and reduced bioavailability of nitric oxide, all of which may exacerbate renal ischemia-reperfusion injury.
Systemic inflammatory response: Contact of blood with the artificial surfaces of the CPB circuit activates complement, neutrophils, and inflammatory cytokines — creating a systemic inflammatory response that damages the renal endothelium and promotes tubular cell apoptosis.
Microemboli: Particulate and gaseous microemboli generated during CPB lodge in small renal vessels, causing focal ischemic injury and inflammatory activation.
Nephrotoxic medications: Contrast agents used in preoperative cardiac catheterization, perioperative antibiotics (aminoglycosides, vancomycin), and NSAIDs for postoperative pain management all contribute nephrotoxic burden that compounds CPB-related injury.
Risk Stratification: The Critical Role of Preoperative Creatinine
Najafi’s Key Contribution: Is Creatinine Reliable?
Serum creatinine is still the most important determinant in the assessment of perioperative renal function and in the prediction of adverse outcome in cardiac surgery. Many biomarkers have been studied to date; still, there is no surrogate for serum creatinine measurement in clinical practice because it is feasible and inexpensive. High levels of serum creatinine and its equivalents have been the most important preoperative risk factor for postoperative renal injury.
Najafi’s specific contribution was to interrogate the reliability of this relationship — recognizing that serum creatinine is an imperfect marker of glomerular filtration rate, particularly in elderly, female, or cachectic patients whose muscle mass is low. A “normal” creatinine in such a patient may mask significantly reduced GFR — a phenomenon termed occult renal insufficiency:
Occult renal insufficiency is usually defined as eGFR < 60 mL/min when creatinine is in normal range. Several studies have shown that the incidence of morbidity and mortality after cardiac surgery is higher in patients with occult renal insufficiency.
This finding has critical practical implications: a patient with a creatinine of 0.9 mg/dL — technically within the normal reference range — may have an eGFR of 45 mL/min if they are elderly and sarcopenic. Using creatinine alone without calculating eGFR misclassifies this patient as “normal renal function” and underestimates their CSA-AKI risk.
Established Preoperative Risk Factors
Preoperative risk factors frequently identified for CSA-AKI include advanced age, female sex, higher body mass index, proteinuria, and the presence of systemic comorbidities including hypertension, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, left ventricular dysfunction, and perioperative anemia. Patients with chronic kidney disease have lower kidney reserve, and during cardiac surgery the kidney can be overwhelmed by surgical stressors, inflammation, and oxidative stress, resulting in further decline in glomerular filtration rate.
The major risk scoring systems for CSA-AKI include:
- Cleveland Clinic Score (Thakar): 13 preoperative variables; validated for predicting dialysis requirement
- Mehta Score: bedside tool based on 8 variables; predicts postoperative dialysis
- Toronto Simplified Renal Index: simplified 3-variable model
All three models consistently identify preoperative renal dysfunction as the single most important risk factor — confirming Najafi’s core finding.
Prevention Strategies: Protecting the Kidney Before, During, and After Surgery
Preoperative Optimization
- Identify and address occult renal insufficiency: calculate eGFR, not just creatinine, in all preoperative patients
- Optimize hydration: correct volume depletion before surgery; avoid preoperative fasting-induced hypovolemia
- Withhold nephrotoxins: stop NSAIDs, minimize contrast exposure, delay surgery after contrast nephropathy
- Optimize cardiac function: improving preoperative cardiac output reduces intraoperative hypoperfusion
Intraoperative Management
Despite often being markedly fluid-positive immediately after cardiac surgery, patients may nevertheless be volume-depleted intravascularly. Diuretics should be administered selectively and with specific fluid-management goals in mind because the liberal, indiscriminate use of diuretic therapy in the early postoperative timeframe may exacerbate hypovolemia and, therefore, AKI.
Key intraoperative renoprotective strategies:
- Mean arterial pressure targets: maintaining MAP > 65–70 mmHg during CPB reduces renal ischemia; individualized higher targets (MAP > 75–80 mmHg) in patients with pre-existing hypertension or CKD
- Minimizing CPB duration: every 30 minutes of additional CPB time increases CSA-AKI risk — surgical efficiency directly protects the kidney
- Pulsatile flow: some evidence that pulsatile CPB preserves medullary perfusion better than non-pulsatile — increasingly used in high-risk patients
- Off-pump CABG: eliminating CPB by performing bypass grafting on a beating heart — reduces but does not eliminate AKI risk
Novel Preventive Approaches
A randomized trial demonstrated that perioperative intravenous amino acid infusion reduced AKI incidence, mechanistically attributed to improved renal perfusion and oxygen delivery. This trial redefined renoprotective strategies, shifting paradigms from reactive to proactive hemodynamic and metabolic support.
Novel Biomarkers: Beyond Creatinine
The Early Detection Gap
The 12–24 hour lag between renal injury and creatinine rise is the central limitation of current CSA-AKI diagnosis. Novel biomarkers that detect tubular injury before creatinine rises have been intensively investigated:
Except for the tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 (TIMP-2 × IGFBP7) ratio, other diagnostic biomarkers with acceptable sensitivity and specificity are still lacking.
The TIMP-2 × IGFBP7 product — marketed as the NephroCheck test — is currently the only FDA-cleared biomarker for early CSA-AKI detection, measuring cell cycle arrest markers that rise within hours of tubular stress. Other biomarkers under investigation include NGAL, KIM-1, L-FABP, cystatin C, and proenkephalin.
Conclusion
Cardiac surgery-associated acute kidney injury is simultaneously one of medicine’s most common serious complications and one of its most preventable — when risk is identified early, perioperative management is optimized, and nephrotoxins are scrupulously avoided. The research of Mohammad Najafi at Tehran Heart Center — establishing the critical importance of preoperative creatinine and eGFR in predicting CSA-AKI, and specifically exposing the danger of occult renal insufficiency masked by normal creatinine values — has contributed foundational evidence that every cardiac surgeon and anesthesiologist should incorporate into preoperative assessment.
Creatinine is the mainstay in predicting risk models, and risk factor reduction has enhanced its importance in outcome prediction. The future perspective is the development of new definitions and novel tools for the early diagnosis of AKI largely based on serum creatinine and a panel of novel biomarkers.
Your next steps as a patient scheduled for cardiac surgery or a clinician managing cardiac surgical patients:
- Ensure preoperative GFR is calculated — not just creatinine — for every patient before cardiac surgery; occult renal insufficiency (eGFR < 60 with normal creatinine) substantially increases CSA-AKI risk and should trigger enhanced perioperative renal monitoring
- Ask your cardiac surgical team about their institutional CSA-AKI prevention protocol — centers with formal protocols (MAP targets, CPB management, nephrotoxin avoidance, fluid management algorithms) have meaningfully lower AKI rates than those without
- Understand that contrast nephropathy from preoperative cardiac catheterization adds to surgical AKI risk — whenever possible, allow 48–72 hours between catheterization and surgery for contrast clearance
- If you have pre-existing CKD, request nephrology co-management before and after cardiac surgery — a nephrologist’s involvement in perioperative care significantly improves renal outcome monitoring and intervention timing
- Monitor creatinine AND urine output postoperatively — creatinine alone misses early AKI; oliguria (< 0.5 mL/kg/hour for ≥ 6 hours) is an equally important early warning that precedes creatinine changes
- Recognize that even “complete” creatinine recovery after CSA-AKI does not eliminate long-term risk — follow-up eGFR monitoring at 3 months, 6 months, and annually after cardiac surgery is recommended for all patients who developed any degree of postoperative AKI